Prostate Cancer, Prostatic Neoplasms
Conditions
Brief summary
To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
Detailed description
In summary, in vitro and in vivo studies, as well as early phase clinical trial, have shown a promising role for both calcitriol and NSAIDs in the treatment of prostate cancer. Moreover, calcitriol and NSAIDs both exert their antiproliferative effect by decreasing prostaglandin levels, but they do so by different mechanisms. Thus, there is reason to believe that their combined effects on prostaglandins may be synergistic. Preliminary in vitro assays in which calcitriol is given in combination with one of two different NSAIDs (Naprosyn or sulindac) to LNCaP cell lines have indicated such synergy. This observation provides the rational for using them in combination for the treatment of prostate cancer. In addition, it is hoped that any synergy noted would allow for the use of lower doses of NSAIDs.
Interventions
DRUGCalcitriol
0.5 micrograms/kilogram q weekly
DRUGNaproxen-n-butyl nitrate
400 mg BID, oral
Sponsors
Novacea
Stanford University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Must give written informed consent * Histologically confirmed adenocarcinoma of the prostate * Biochemical relapse after primary radiation therapy or surgery * Normal testosterone levels * 3 rising PSA after nadir, with interval between PSA determinations \> 2 weeks
Exclusion criteria
* Local recurrence by CT scan * Distant metastases by bone scan * Hypercalcemia * Nephrolithiasis * Renal insufficiency (serum creatinine \> 1.8 mg/dl) * Pancreatitis * History of ulcer or gastrointestinal bleeding * More than 6 months of hormone ablation therapy * Concurrent therapy for prostate cancer * Uncontrolled HTN * H/O MI, CVA, TIA * Known coronary disease/cerebrovascular disease * Platelet counts \<50 * Patients on anticoagulants * Patients on lithium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA response - 50% PSA decline, PSA progression, PSA response duration, progressive disease, time to PSA progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progressive disease in this study's patients, who would be treated with calcitriol and naprosyn, will be compared to that in historical controls of patients treated with calcitriol alone. | — |
Countries
United States
Outcome results
None listed